Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications

Study Description:

This is a phase 1/2 open-label trial to study the safety and to explore the biological efficacy of tofacitinib in patients with confirmed and symptomatic inflammatory complications (gastrointestinal [GI], skin, lung) related to chronic granulomatous disease (CGD). After a 3-month regimen, participants inflammatory complications will be objectively assessed.

Primary Objective:

To assess the safety of tofacitinib during the study period in patients with CGD.

Secondary Objectives:

• To assess the overall clinical response for the specific inflammatory manifestations.
• To assess the biological effect of tofacitinib on interferon (IFN)-induced gene expression in CGD.

Primary Endpoints:

• Rate of infection.
• Rate of treatment-related toxicities.
• Rate of adverse events (AEs).
• Incidence of serious bacterial, mycobacterial, fungal, or viral infections defined as infections that require medical assessment or hospitalization.

Secondary Endpoints:

CGD-related inflammatory bowel disease (IBD):

• Change in modified Harvey-Bradshaw Index (HBI).
• Change in histopathological endoscopy.

Inflammatory lung disease:

• Change in forced expiratory volume (FEV1).
• Change in diffusing capacity for carbon monoxide (DLCO).
• Change in computed tomography (CT) radiography.
• Change in 6-minute walk.

Skin disease:

• Change in presence of skin flares or ulcerations by objective photography evaluation.

Gene expression:

1.Change in IFN gene module enrichment score derived from whole blood RNA expression data.

• INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

• Aged >=18 years.
• Enrolled on NIH study 93-I-0119.
• Has a documented diagnosis of one or more of the following and is not controlled under current therapy (per investigator assessment):

• Endoscopically diagnosed mild-to-severe CGD-related IBD.
• Radiographic or PFT changes (DLCO<60%, FEV1<70%) consistent with CGD-related inflammatory lung disease.
• Any inflammatory skin disease related to CGD (eg, hidradenitis suppurativa or granulomatous skin disease).
• Able to provide informed consent.
• Participants who can become pregnant or who can impregnate their partner must agree to use at least one highly effective method of contraception when engaging in sexual activities that can result in pregnancy, starting at the first dose of tofacitinib until 2 days after the last dose. Highly effective methods include a barrier (eg, condom, diaphragm, cervical cap), intrauterine device, or hormonal contraception.

Exclusion criteria

An individual who meets any of the following criteria will be excluded from participation in this study:

• Known allergy or hypersensitivity to any component of the tofacitinib formulation.
• Known allergy or hypersensitivity to any component of the acyclovir or valacyclovir formulation.
• Active or latent tuberculosis.
• Infection with hepatitis B or C, or HIV.
• Active EBV infection.
• History of GI perforation.
• History of malignancy (except for nonmelanoma skin cancer).
• Concomitant use of acetylsalicylic acid and/or NSAIDs that cannot be safely discontinued.
• History of connective tissue disease.
• End-stage renal disease or chronic kidney disease, defined as estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m^2.
• Evidence of other invasive or systemic fungal, bacterial, or viral infections requiring therapy.
• Pregnant.
• Breastfeeding.
• Current use of inhaled tobacco products, vaping products, inhaled cannabis, or other illicit inhaled drugs.
• Current use of strong CYP3A4 inducer and unable to discontinue at least 14 days before beginning of tofacitinib regimen.
• Concomitant medical condition that could interfere with study drug evaluation or that is a contraindication to the proposed investigational treatment based upon known agent safety profile or toxicities.
• Any of the following laboratory abnormalities:

• Alkaline phosphatase and either ALT or AST >2.5 times the upper limit of normal (ULN).
• Serum creatinine level >5 mg/dL.
• Absolute neutrophil count (ANC) <1000 cells/microL.
• Lymphocyte count <500 cells/microL.
• History of unprovoked deep vein thrombosis, pulmonary embolism, or other thrombotic events.
• History of heart failure.
• Current immobilization, ie, bed-bound and unable to ambulate.
• Exposure to any investigational agent within the last 4 weeks.
• Any other finding that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety or reactogenicity, or a participant s ability to give informed consent, or increase the risk of having an adverse outcome from participating in the study.